Last reviewed · How we verify
NCT06772376
SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer
trial testing SERS sensor based on CHA reaction in Lung Cancer in Normal and Malignant Tumors in 400 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Fuzhou General Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 May 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
Drugs / interventions tested
- SERS sensor based on CHA reaction
Conditions studied
- Lung Cancer in Normal and Malignant Tumors — all drugs for Lung Cancer in Normal and Malignant Tumors →
Sponsor
Fuzhou General Hospital
Who can join
18 and older, any sex, with Lung Cancer in Normal and Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Summary:This study is a prospective, multicenter clinical study. In previous studies, we successfully constructed a CHA reaction-mediated self-calibrated SERS biosensor for the detection of EGFR mutation typing (Del-19, T790M, L858R) in lung cancer patients, and verified that the accuracy, sensitivity, and specificity of the SERS biosensor exceeded 95% in a small sample of 32 patients. In order to obtain the highest level of clinical evidence and truly achieve clinical transformation, this prospective, multicenter clinical study aims to verify the analytical efficiency of the SERS biosensor for EGFR mutation typing in patients with advanced lung cancer. Purpose：This prospective, multicenter clinical study aims to verify the analytical efficacy of the previously constructed CHA reaction-mediated self-calibrated SERS biosensor in EGFR mutation typing in patients with advanced lung cancer. Research subjects: The patients enrolled in this project are confirmed to be advanced non-small cell lung cancer (NSCLC). Enrollment will be completed in 25 centers and the enrollment will be competitive. Research location: 900th Hospital of Joint Logistics Support Force Research intervention: None Study duration: Patients will be enrolled from June 2024 to June 2025. Subject participation time: Telephone follow-up will be conducted every three months until the end of the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nanomaterial-Mediated Electrochemical and Optical Biosensors and Their Application in Tumour Marker Detection.
Wang X, Hei J, Zhao T, Liu X, et al · · 2025 · PMID 41013140 · DOI 10.3390/s25185902
Verify or expand the search:
- PubMed search for NCT06772376
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fuzhou General Hospital trials
Trials by the same sponsor.
- NCT06772363 — SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis · not yet recruiting
- NCT06775587 — SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules · not yet recruiting
- NCT06775002 — SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type · not yet recruiting
- NCT06775015 — SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer · not yet recruiting
- NCT07458919 — Therapy for Advanced NSCLC With EGFR 19delins Mutation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06772376 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuzhou General Hospital
- Last refreshed: 31 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06772376.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing